Merck & Co., Inc. $MRK Shares Sold by Gateway Investment Advisers LLC

Key Points

• Gateway Investment Advisers reduced its Merck stake by 2.4% in the second quarter, selling 10,795 shares while retaining 433,052 shares valued at approximately $55.6 million. Institutional investors and hedge funds collectively own 76.07% of MRK.
• Merck reported quarterly revenue of $16.61 billion, exceeding estimates, while revenue increased 5.1% year over year. The company declared a quarterly dividend of $0.85 per share, equivalent to a 2.5% annualized yield.
• Analyst sentiment remains favorable, with 15 Buy ratings and an average target price of $135.50, but investors face risks from Keytruda concentration and future patent competition; insiders have also sold nearly $30 million of shares over the past 90 days.

Gateway Investment Advisers LLC lowered its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 2.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 433,052 shares of the company's stock after selling 10,795 shares during the quarter. Gateway Investment Advisers LLC's holdings in Merck & Co., Inc. were worth $55,647,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of MRK. Kingdom Financial Group LLC. purchased a new position in Merck & Co., Inc. during the fourth quarter worth about $25,000. Abound Financial LLC acquired a new position in shares of Merck & Co., Inc. during the 4th quarter worth $26,000. Prosperity Bancshares Inc purchased a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at about $26,000. High Note Wealth LLC grew its holdings in Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company's stock valued at $31,000 after buying an additional 109 shares during the last quarter. Finally, IFC & Insurance Marketing Inc. purchased a new stake in Merck & Co., Inc. during the 4th quarter worth about $31,000. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Stock Up 2.0%

MRK stock opened at $135.57 on Friday. Merck & Co., Inc. has a 52-week low of $77.58 and a 52-week high of $135.68. The firm has a market capitalization of $334.49 billion, a P/E ratio of 108.46, a P/E/G ratio of 5.73 and a beta of 0.19. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The company's 50 day simple moving average is $125.25 and its 200-day simple moving average is $119.83.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.05% and a net margin of 4.77%.The company had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. During the same quarter in the prior year, the company earned $2.13 EPS. The firm's quarterly revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities research analysts anticipate that Merck & Co., Inc. will post 2.77 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be given a $0.85 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.5%. Merck & Co., Inc.'s payout ratio is currently 272.00%.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst upgrades and higher valuations: Daiwa Securities upgraded Merck to “outperform” with a $143 price target, while other analyst commentary placed fair-value estimates in the $140–$155 range. A separate valuation assessment raised fair value from $132.78 to $136.85, citing pipeline progress and recent business-development activity. Merck fair value article
• Positive Sentiment: Shares reached a record level: Merck was among the companies touching fresh all-time highs, signaling strong recent momentum and investor confidence in its earnings outlook. Merck all-time high article
• Positive Sentiment: Pipeline and core products support growth: Analysts highlighted Merck’s late-stage pipeline, business-development efforts and continued demand for Keytruda. Recent quarterly results also showed revenue of $16.61 billion, above expectations, with oncology and Animal Health cited as important contributors. Merck earnings call analysis
• Neutral Sentiment: Dividend provides income support: Merck declared a quarterly dividend of $0.85 per share, or $3.40 annualized. The payout may support demand for the stock, although the reported payout ratio is elevated.
• Negative Sentiment: Cluster of executive sales: Several executives sold shares, including Jennifer Zachary’s approximately $10.7 million sale, Chirfi Guindo’s $1.35 million sale and Richard Deluca’s additional $1.54 million sale. These transactions reduced their holdings substantially and could weigh modestly on sentiment, though insiders retained shares.
• Negative Sentiment: Keytruda concentration risk: Keytruda remains Merck’s main growth engine, but future patent loss and increasing competition could pressure sales and earnings. Investors will look for newer products and pipeline candidates to offset that risk. Keytruda growth outlook article

Insider Activity

In other Merck & Co., Inc. news, EVP David R. Maraldo sold 18,706 shares of the stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the transaction, the executive vice president owned 18,212 shares in the company, valued at $2,344,248.64. This trade represents a 50.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP David Michael Williams sold 52,847 shares of Merck & Co., Inc. stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the transaction, the executive vice president owned 31,716 shares in the company, valued at $4,084,069.32. The trade was a 62.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 228,238 shares of company stock valued at $29,977,783. Insiders own 0.17% of the company's stock.

Analyst Ratings Changes

Several research firms have recently issued reports on MRK. Daiwa Securities Group upgraded Merck & Co., Inc. from a "neutral" rating to an "outperform" rating and set a $143.00 price objective on the stock in a report on Wednesday. Scotiabank upped their target price on Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a "sector outperform" rating in a research report on Tuesday, June 30th. CICC Research began coverage on Merck & Co., Inc. in a research note on Wednesday, June 24th. They set an "outperform" rating and a $138.00 target price for the company. Bank of America raised their price target on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a "buy" rating in a research report on Tuesday, June 30th. Finally, Royal Bank Of Canada restated an "outperform" rating and issued a $142.00 target price on shares of Merck & Co., Inc. in a research report on Wednesday, July 8th. Fifteen investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat, Merck & Co., Inc. presently has an average rating of "Moderate Buy" and an average target price of $135.50.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source